Opioid Withdrawal Management with Lofexidine and Clonidine

Mechanism of Action and Pharmacology

• Lofexidine is FDA-approved specifically for opioid withdrawal management with fewer hypotensive side effects than clonidine, though both are α2-adrenergic agonists with similar efficacy in reducing withdrawal symptoms 1, 2

Key Differences

FDA Approval Status

• Lofexidine is FDA-approved specifically for management of opioid withdrawal symptoms 1, 2

Efficacy in Withdrawal Management

• Both medications are less effective than buprenorphine for managing opioid withdrawal in terms of severity reduction and treatment completion 3

Treatment Retention

• However, both medications show lower treatment completion rates compared to buprenorphine 3

Practical Considerations for Clinical Use

Dosing

• Both medications should be started at low doses and titrated based on withdrawal symptoms and blood pressure monitoring 1, 2

Place in Therapy

• Both are considered second-line options after buprenorphine for managing opioid withdrawal 4
• Buprenorphine has been shown to be more effective than both clonidine and lofexidine for managing withdrawal symptoms, with lower average withdrawal scores and higher treatment completion rates 3